Overview

Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer

Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
Investigation on safety, tolerability and efficacy of parvovirus H-1 (ParvOryx) in subjects suffering from metastatic, inoperable pancreatic cancer with at least one hepatic metastasis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Oryx GmbH & Co. KG